Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod Extension Study in Relapsing Multiple Sclerosis
NCT01047319Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2010
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of laquinimod in multiple sclerosis (MS), sponsored by Teva Pharmaceutical Industries Ltd.. Started May 2010; status: terminated.
02
Drugs
laquinimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01047319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01047319.